Danaher Corporation (NYSE:DHR) is one of the best strong buy healthcare stocks to buy now. On July 23, UBS lowered the firm’s ...

Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Danaher Corp (DHR) reports robust free cash flow and bioprocessing growth, while navigating global trade tensions and Life ...

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Danaher ( (DHR) ) has issued an update.

Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, expectations were $1.64. Margaux: My name is Margaux, and I’ll be your conference ...

Danaher (NYSE:DHR) stock falls even as the company beats Q2 2025 forecasts despite an underperformance at its Life Sciences ...

Danaher reported generating $1.1 billion in free cash flow during the quarter, with adjusted diluted net earnings per share increasing by approximately 5% year-over-year. This financial strength ...

Danaher Corporation (NYSE:DHR) is one of the 13 Best Large Cap Stocks to Buy Right Now. On May 29, Danaher Corporation ...

Danaher Corp. (DHR) on Tuesday reported second-quarter earnings of $555 million. The Washington-based company said it had profit of 77 cents per share.

This was the stock's third consecutive day of losses.

Danaher Corp. has emerged as the leading bidder for biotechnology supplier Abcam Plc, according to people familiar with the matter. Danaher has pulled ahead of other bidders and is negotiating ...